Free tool
FAERS Monitor: Austedo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209885 or its brand name (Austedo, Deutetrabenazine). Reports on generic versions are filed under their own applications.
Reports
5,937
Serious
2,709
46% of reports
Hospitalization
817
Death reported
498
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective778
- death435
- depression388
- dyskinesia386
- tremor294
- product use issue280
- somnolence271
- suicidal ideation260
- fall255
- insomnia255
- product use in unapproved indication255
- fatigue248
- off label use247
- tardive dyskinesia189
- dizziness180
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 86 |
| 2018 | 405 |
| 2019 | 601 |
| 2020 | 708 |
| 2021 | 778 |
| 2022 | 527 |
| 2023 | 503 |
| 2024 | 950 |
| 2025 | 780 |
| 2026 | 598 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,222 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dyskinesiaSignal | 386 | 34.0 | 30.8 | 12,222 |
| tardive dyskinesiaSignal | 189 | 23.9 | 20.8 | 4,100 |
| suicidal ideationSignal | 260 | 10.1 | 9.0 | 2,123 |
| tremorSignal | 294 | 6.3 | 5.6 | 1,309 |
| depressionSignal | 388 | 6.0 | 5.5 | 1,645 |
| product use issueSignal | 280 | 5.3 | 4.7 | 976 |
| somnolenceSignal | 271 | 4.8 | 4.2 | 811 |
| product use in unapproved indicationSignal | 255 | 3.6 | 3.2 | 493 |
| insomniaSignal | 255 | 3.4 | 3.0 | 433 |
| fallSignal | 255 | 2.7 | 2.4 | 279 |
| drug ineffectiveSignal | 778 | 2.1 | 2.0 | 472 |
| death | 435 | 1.8 | 1.6 | 157 |
| dizziness | 180 | 1.3 | 1.1 | 11 |
| fatigue | 248 | 1.1 | 1.0 | 4 |
| off label use | 247 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.